NCT07844772Recruiting
Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque Psoriasis
Evaluation of the Association of Serum Substance P Levels With Neuropathic Pain, Central Sensitization, Disease Severity, and Quality of Life Across Different Treatment Groups in Patients With Chronic Plaque Psoriasis
Source: ClinicalTrials.gov · Last updated 28 Sept 2026
Brief summary (registry, in English)
The goal of this observational study is to better understand whether blood levels of Substance P are related to pain, itching, altered pain sensations, central sensitization, psoriasis severity, and quality of life in adults with chronic plaque psoriasis. The main questions this study aims to answer are: Are serum Substance P levels associated with neuropathic pain features, central sensitization, psoriasis severity, pain, itching, and quality of life? Do serum Substance P levels and these clinical features differ among patients receiving different psoriasis treatments? Researchers will compare three groups of patients: those receiving IL-17 inhibitor treatment, those receiving conventional systemic treatment with methotrexate or acitretin, and those receiving topical treatment only or no current treatment. Participants will: Have their psoriasis severity assessed and complete questionnaires about pain, itching, central sensitization, and quality of life. Undergo a neurological examination. Participants who report pain will also be evaluated for neuropathic pain features using the DN4 questionnaire. Provide a blood sample for measurement of serum Substance P and routine laboratory tests. Undergo electromyography and nerve conduction studies if peripheral neuropathy is suspected during the neurological evaluation. No treatment will be assigned or changed as part of this study.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 17 Sept 2026
- Start date
- Jun 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- Istanbul Training and Research Hospital
- Diseases
- Psoriasis
- NCT number
- NCT07844772
What you commit to
- Study type: Observational
- Planned participants: 100
- From Jun 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Neuropathy related to uremia or thyroid disease
- Chronic renal failure or chronic liver failure
- Active infection
- Active malignancy
Lab values
- Known diabetes mellitus, HbA1c ≥6.5%, or fasting plasma glucose ≥126 mg/dL
Other
- Vitamin B12 level \<200 pg/mL
- Known peripheral neuropathy or peripheral neuropathy detected during neurological evaluation and/or electromyography
- Active inflammatory arthritis in patients with psoriatic arthritis
- Pregnancy or breastfeeding
- Chronic heavy alcohol use
Who the study is looking for
- Age ≥18 years
- Diagnosis of chronic plaque psoriasis
- Ability and willingness to provide written informed consent
- For the IL-17 inhibitor group: current treatment with an IL-17 inhibitor for at least 8 weeks
- For the conventional systemic therapy group: current treatment with methotrexate or acitretin for at least 6 weeks
- For the topical therapy/treatment-naive group: topical therapy only or no previous treatment, with no systemic therapy, biologic therapy, or phototherapy within the previous 6 months
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istanbul Training and Research Hospital Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.